Crescent Biopharma (CBIO) Non Operating Income (2013 - 2026)
Crescent Biopharma (CBIO) posted quarterly Non Operating Income of -$3.3 million for Q2 2026, down 533.82% year-over-year from $760000.0 in Q2 2025, and down 128.01% quarter-over-quarter from -$1.4 million in Q1 2026.
Crescent Biopharma (CBIO) Non Operating Income (2013 - 2026) Analysis & Trends
Crescent Biopharma (CBIO) has reported Non Operating Income for 11 consecutive years, with -$3.3 million the latest figure, recorded in Q2 2026.
- In Q2 2026, Non Operating Income fell 533.82% year-over-year to -$3.3 million; the TTM figure through Jun 2026 stood at -$2.8 million (down 170.99% YoY), while the FY2025 annual figure was -$690000.0, down 131.94% from the prior year.
- Non Operating Income declined to -$3.3 million in Q2 2026 per CBIO's latest filing, from -$1.4 million in the prior quarter.
- Across five years, Non Operating Income topped out at $1.4 million in Q3 2024 and bottomed at -$3.3 million in Q2 2026.
- Historically, Non Operating Income has averaged $186344.1 across 5 years, with a median of $445277.0 in 2023.
- Annual changes were most pronounced in 2022 — Non Operating Income soared 9180.3% — and 2026, when it sank 533.82%.
- Crescent Biopharma's Non Operating Income stood at $378265.0 in 2022, then soared by 35.41% to $512194.0 in 2023, then surged by 31.98% to $676000.0 in 2024, then increased by 12.43% to $760000.0 in 2025, then tumbled by 533.82% to -$3.3 million in 2026.
- Business Quant data shows CBIO's Non Operating Income at -$3.3 million in Q2 2026, -$1.4 million in Q1 2026, and $760000.0 in Q2 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non Op. Inc. (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn | 234.30 Mn |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn | - |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn | - |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn | - |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn | -53.64 Mn |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn | - |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - | -51.63 Mn |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn | - |
| 10 | Crescent Biopharma | 1.05 Bn | 875.92 Mn | - | -3.30 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -3.30 Mn |
| Mar 31, 2026 | -1.45 Mn |
| Mar 31, 2025 | 1.15 Mn |
| Dec 31, 2024 | 676,000.00 |
| Sep 30, 2024 | 1.41 Mn |
| Jun 30, 2024 | 262,288.00 |
| Mar 31, 2024 | 378,360.00 |
| Dec 31, 2023 | 512,194.00 |
| Sep 30, 2023 | 610,978.00 |
| Jun 30, 2023 | 671,033.00 |
| Mar 31, 2023 | 581,668.00 |
| Dec 31, 2022 | 378,265.00 |
| Sep 30, 2022 | 243,597.00 |
| Jun 30, 2022 | 85,588.00 |
| Mar 31, 2022 | 7,069.00 |
| Dec 31, 2021 | 4,076.00 |
| Sep 30, 2021 | 4,625.00 |
| Jun 30, 2021 | 5,221.00 |
| Mar 31, 2021 | 5,846.00 |
| Dec 31, 2020 | 5,608.00 |